163 related articles for article (PubMed ID: 29915633)
1. SATB2 Shows Different Profiles Between Appendiceal Adenocarcinomas Ex Goblet Cell Carcinoids and Appendiceal/Colorectal Conventional Adenocarcinomas: An Immunohistochemical Study With Comparison to CDX2.
Yang C; Sun L; Zhang L; Zhou L; Niu D; Cao W; Li Z; Huang X; Kang Q; Jia L; Platik M; Liu X; Lai J; Cao D
Gastroenterology Res; 2018 Jun; 11(3):221-230. PubMed ID: 29915633
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic Utility of SATB2 in Metastatic Krukenberg Tumors of the Ovary: An Immunohistochemical Study of 70 Cases With Comparison to CDX2, CK7, CK20, Chromogranin, and Synaptophysin.
Yang C; Sun L; Zhang L; Zhou L; Zhao M; Peng Y; Niu D; Li Z; Huang X; Kang Q; Jia L; Lai J; Cao D
Am J Surg Pathol; 2018 Feb; 42(2):160-171. PubMed ID: 28914716
[TBL] [Abstract][Full Text] [Related]
3. SATB2 Expression Distinguishes Ovarian Metastases of Colorectal and Appendiceal Origin From Primary Ovarian Tumors of Mucinous or Endometrioid Type.
Moh M; Krings G; Ates D; Aysal A; Kim GE; Rabban JT
Am J Surg Pathol; 2016 Mar; 40(3):419-32. PubMed ID: 26551622
[TBL] [Abstract][Full Text] [Related]
4. Appendiceal goblet cell carcinoids and adenocarcinomas ex-goblet cell carcinoid are genetically distinct from primary colorectal-type adenocarcinoma of the appendix.
Jesinghaus M; Konukiewitz B; Foersch S; Stenzinger A; Steiger K; Muckenhuber A; Groß C; Mollenhauer M; Roth W; Detlefsen S; Weichert W; Klöppel G; Pfarr N; Schlitter AM
Mod Pathol; 2018 May; 31(5):829-839. PubMed ID: 29327707
[TBL] [Abstract][Full Text] [Related]
5. Role of SATB2 in distinguishing the site of origin in glandular lesions of the bladder/urinary tract.
Giannico GA; Gown AM; Epstein JI; Revetta F; Bishop JA
Hum Pathol; 2017 Sep; 67():152-159. PubMed ID: 28711650
[TBL] [Abstract][Full Text] [Related]
6. Loss of SATB2 Expression in Colorectal Carcinoma Is Associated With DNA Mismatch Repair Protein Deficiency and BRAF Mutation.
Ma C; Olevian DC; Lowenthal BM; Jayachandran P; Kozak MM; Chang DT; Pai RK
Am J Surg Pathol; 2018 Oct; 42(10):1409-1417. PubMed ID: 30001238
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical characterization of appendiceal mucinous neoplasms and the value of special AT-rich sequence-binding protein 2 in their distinction from primary ovarian mucinous tumours.
Strickland S; Parra-Herran C
Histopathology; 2016 Jun; 68(7):977-87. PubMed ID: 26542609
[TBL] [Abstract][Full Text] [Related]
8. SATB2 is a supplementary immunohistochemical marker to CDX2 in the diagnosis of colorectal carcinoma metastasis in an unknown primary.
Dabir PD; Svanholm H; Christiansen JJ
APMIS; 2018 Jun; 126(6):494-500. PubMed ID: 29924451
[TBL] [Abstract][Full Text] [Related]
9. SATB2 Is Superior to CDX2 in Distinguishing Signet Ring Cell Carcinoma of the Upper Gastrointestinal Tract and Lower Gastrointestinal Tract.
Ma C; Lowenthal BM; Pai RK
Am J Surg Pathol; 2018 Dec; 42(12):1715-1722. PubMed ID: 30212392
[TBL] [Abstract][Full Text] [Related]
10. The utility of PAX8 and SATB2 immunohistochemical stains in distinguishing ovarian mucinous neoplasms from colonic and appendiceal mucinous neoplasm.
Aldaoud N; Erashdi M; AlKhatib S; Abdo N; Al-Mohtaseb A; Graboski-Bauer A
BMC Res Notes; 2019 Nov; 12(1):770. PubMed ID: 31771640
[TBL] [Abstract][Full Text] [Related]
11. Neuroendocrine Markers Insulinoma-Associated Protein 1, Chromogranin, Synaptophysin, and CD56 Show Rare Positivity in Adenocarcinoma Ex-Goblet Cell Carcinoids.
Yang C; Gonzalez I; Zhang L; Cao D
Gastroenterology Res; 2019 Jun; 12(3):120-127. PubMed ID: 31236152
[TBL] [Abstract][Full Text] [Related]
12. SATB2 Versus CDX2: A Battle Royale for Diagnostic Supremacy in Mucinous Tumors.
Brettfeld SM; Ramos BD; Berry RS; Martin DR; Hanson JA
Arch Pathol Lab Med; 2019 Sep; 143(9):1119-1125. PubMed ID: 30838879
[TBL] [Abstract][Full Text] [Related]
13. CDX2, SATB2, GATA3, TTF1, and PAX8 Immunohistochemistry in Krukenberg Tumors.
Chiesa-Vottero A
Int J Gynecol Pathol; 2020 Mar; 39(2):170-177. PubMed ID: 32045390
[TBL] [Abstract][Full Text] [Related]
14. Loss of SATB2 Occurs More Frequently Than CDX2 Loss in Colorectal Carcinoma and Identifies Particularly Aggressive Cancers in High-Risk Subgroups.
Schmitt M; Silva M; Konukiewitz B; Lang C; Steiger K; Halfter K; Engel J; Jank P; Pfarr N; Wilhelm D; Foersch S; Denkert C; Tschurtschenthaler M; Weichert W; Jesinghaus M
Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944797
[TBL] [Abstract][Full Text] [Related]
15. Colitis-associated colorectal adenocarcinomas are frequently associated with non-intestinal mucin profiles and loss of SATB2 expression.
Iwaya M; Ota H; Tateishi Y; Nakajima T; Riddell R; Conner JR
Mod Pathol; 2019 Jun; 32(6):884-892. PubMed ID: 30710095
[TBL] [Abstract][Full Text] [Related]
16. Impact of Neoadjuvant Chemotherapy on SATB2 Expression in Colorectal Carcinomas: SATB2 Positivity is Preserved in Most Cases, but Down-Expressed in Effective Cases of Chemotherapy.
Asahina Y; Hashimoto H; Aihara M; Noie T; Morikawa T
Int J Surg Pathol; 2023 Feb; 31(1):46-55. PubMed ID: 35343276
[TBL] [Abstract][Full Text] [Related]
17. Mutational landscape of goblet cell carcinoids and adenocarcinoma ex goblet cell carcinoids of the appendix is distinct from typical carcinoids and colorectal adenocarcinomas.
Johncilla M; Stachler M; Misdraji J; Lisovsky M; Yozu M; Lindeman N; Lauwers GY; Odze RD; Srivastava A
Mod Pathol; 2018 Jun; 31(6):989-996. PubMed ID: 29422640
[TBL] [Abstract][Full Text] [Related]
18. The morphologic spectrum of ovarian metastases of appendiceal adenocarcinomas: a clinicopathologic and immunohistochemical analysis of tumors often misinterpreted as primary ovarian tumors or metastatic tumors from other gastrointestinal sites.
Ronnett BM; Kurman RJ; Shmookler BM; Sugarbaker PH; Young RH
Am J Surg Pathol; 1997 Oct; 21(10):1144-55. PubMed ID: 9331286
[TBL] [Abstract][Full Text] [Related]
19. SATB2 is a supportive marker for the differentiation of a primary mucinous tumor of the ovary and an ovarian metastasis of a low-grade appendiceal mucinous neoplasm (LAMN): A series of seven cases.
Schmoeckel E; Kirchner T; Mayr D
Pathol Res Pract; 2018 Mar; 214(3):426-430. PubMed ID: 29487003
[TBL] [Abstract][Full Text] [Related]
20. CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas.
Werling RW; Yaziji H; Bacchi CE; Gown AM
Am J Surg Pathol; 2003 Mar; 27(3):303-10. PubMed ID: 12604886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]